[
  {
    "ts": "2025-09-01T18:18:42+00:00",
    "headline": "Podcast: Alternative testing models to shape toxicology “with time”",
    "summary": "Annabel Kartal-Allen chats with Charles River's Head of GLBL Toxicology, Steve Bulera, about the current state of the alternative testing space, the sector's future trajectory and the hurdles that must be overcome to implement these technologies over animal testing.",
    "url": "https://www.clinicaltrialsarena.com/features/podcast-alternative-testing-models-to-shape-toxicology-with-time/",
    "source": "Clinical Trials Arena",
    "provider": "yfinance",
    "raw": {
      "id": "3712d857-2028-3129-8c3c-4ef37fd9d5c5",
      "content": {
        "id": "3712d857-2028-3129-8c3c-4ef37fd9d5c5",
        "contentType": "STORY",
        "title": "Podcast: Alternative testing models to shape toxicology “with time”",
        "description": "",
        "summary": "Annabel Kartal-Allen chats with Charles River's Head of GLBL Toxicology, Steve Bulera, about the current state of the alternative testing space, the sector's future trajectory and the hurdles that must be overcome to implement these technologies over animal testing.",
        "pubDate": "2025-09-01T18:18:42Z",
        "displayTime": "2025-09-01T18:18:42Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/clinical_trials_arena_396/e7e9589bd6cf72b6f9cc00d067d1e74b",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qok9qaVdUm7lffYar1gq9A--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/clinical_trials_arena_396/e7e9589bd6cf72b6f9cc00d067d1e74b.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EpPl5dGKwB.JWeo2lGRAWw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/clinical_trials_arena_396/e7e9589bd6cf72b6f9cc00d067d1e74b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Clinical Trials Arena",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.clinicaltrialsarena.com/features/podcast-alternative-testing-models-to-shape-toxicology-with-time/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/podcast-alternative-testing-models-shape-181842975.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CRL"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-01T14:21:00+00:00",
    "headline": "Charles River Stock May Benefit From Joining EASYGEN Consortium",
    "summary": "CRL joins EASYGEN to speed CAR-T therapy delivery, which may boost patient access and investor sentiment.",
    "url": "https://finance.yahoo.com/news/charles-river-stock-may-benefit-142100527.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "752b1a97-a956-32e9-bf43-6445ba04f1e5",
      "content": {
        "id": "752b1a97-a956-32e9-bf43-6445ba04f1e5",
        "contentType": "STORY",
        "title": "Charles River Stock May Benefit From Joining EASYGEN Consortium",
        "description": "",
        "summary": "CRL joins EASYGEN to speed CAR-T therapy delivery, which may boost patient access and investor sentiment.",
        "pubDate": "2025-09-01T14:21:00Z",
        "displayTime": "2025-09-01T14:21:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/41b7bdd28f63138df08f17b665d3589a",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EzN04L.MG5n2SiOn76bXjg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/41b7bdd28f63138df08f17b665d3589a.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1EIdoTL1xBchT1nrSboC2Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/41b7bdd28f63138df08f17b665d3589a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/charles-river-stock-may-benefit-142100527.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/charles-river-stock-may-benefit-142100527.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVST"
            },
            {
              "symbol": "CRL"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]